SCHOTT Pharma Anticipates Fiscal Year 2025 Impact Due to Slower Syringe Sales

SCHOTT Pharma AG & Co. KGaA announced its fiscal year 2024/2025 revenue growth forecast will likely see a high single-digit to low double-digit percentage, lower than current market expectations. The forecast, detailed in a recent press release, attributes the reduced growth to a decline in syringe demand from a major customer.

This adjustment in revenue projections is likely to result in less expansion of the company's EBITDA margin than previously anticipated by market analysts. Despite this anticipated slower growth, SCHOTT Pharma reaffirmed its mid-term and current fiscal year forecasts.